Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2020
Trifarotene in moderate acne: no study data for the assessment of the added benefit
16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 05 Jul 2020
Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority
1 July 2020 - Informative comparative data are missing / resistance situation not sufficiently considered in approval studies. ...
Posted by Michael Wonder on 15 Jun 2020
Romosozumab in osteoporosis: considerable added benefit for women after menopause
15 June 2020 - Fewer vertebral fractures and fewer other typical fractures in post-menopausal women with severe osteoporosis at high ...
Posted by Michael Wonder on 02 Jun 2020
Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women
2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages ...
Posted by Michael Wonder on 14 May 2020
Belimumab in active systemic lupus erythematosus: additional benefit for children and adolescents
14 May 2020 - Addendum with a new summary; subsequent information enables the benefits to be assessed. ...
Posted by Michael Wonder on 16 Jan 2020
Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children
15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...
Posted by Michael Wonder on 23 Sep 2019
Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations
19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...
Posted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...